Dyfyniad APA

Nazir, J., Berling, M., McCrea, C., Fatoye, F., Bowditch, S., Hakimi, Z., & Wagg, A. (2017). Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK. Pharmacoecon Open.

Dyfyniad Arddull Chicago

Nazir, Jameel, Malin Berling, Charles McCrea, Francis Fatoye, Sally Bowditch, Zalmai Hakimi, and Adrian Wagg. "Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK." Pharmacoecon Open 2017.

Dyfyniad MLA

Nazir, Jameel, et al. "Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK." Pharmacoecon Open 2017.

Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.